Ozemek Cemal, Arena Ross, Rouleau Codie R, Campbell Tavis S, Hauer Trina, Wilton Stephen B, Stone James, Laddu Deepika, Williamson Tamara M, Liu Hongwei, Chirico Daniele, Austford Leslie D, Aggarwal Sandeep
Department of Physical Therapy, College of Applied Health Sciences, University of Illinois at Chicago, Chicago (Drs Ozemek, Arena, and Laddu); TotalCardiology Research Network, Calgary, Canada (Drs Arena, Rouleau, Campbell, Wilton, Stone, Chirico, and Aggarwal and Ms Austford); TotalCardiology™ Rehabilitation, Calgary, Canada (Drs Rouleau and Aggarwal and Ms Hauer); Departments of Psychology (Drs Rouleau, Campbell, and Aggarwal and Ms Williamson), Community Health Sciences (Dr Liu), and Kinesiology (Dr Chirico), University of Calgary, Calgary, Canada; and Libin Cardiovascular Institute, University of Calgary, Calgary, Canada (Drs Wilton, Stone, and Liu).
J Cardiopulm Rehabil Prev. 2023 Mar 1;43(2):109-114. doi: 10.1097/HCR.0000000000000734. Epub 2022 Sep 24.
The objective of this study was to characterize the impact of multimorbidity and cardiorespiratory fitness (CRF) on mortality in patients completing cardiac rehabilitation (CR).
This cohort study included data from patients with a history of cardiovascular disease (CVD) completing a 12-wk CR program between January 1996 and March 2016, with follow-up through March 2017. Patients were stratified by the presence of multimorbidity, which was defined as having a diagnosis of ≥2 noncommunicable diseases (NCDs). Cox regression analyses were used to evaluate the effects of multimorbidity and CRF on mortality in patients completing CR. Symptom-limited exercise tests were completed at baseline, immediately following CR (12 wk), with a subgroup completing another test at 1-yr follow-up. Peak metabolic equivalents (METs) were determined from treadmill speed and grade.
Of the 8320 patients (61 ± 10 yr, 82% male) included in the analyses, 5713 (69%) patients only had CVD diagnosis, 2232 (27%) had CVD+1 NCD, and 375 (4%) had CVD+≥2 NCDs. Peak METs at baseline (7.8 ± 2.0, 6.9 ± 2.0, 6.1 ± 1.9 METs), change in peak METs immediately following CR (0.98 ± 0.98, 0.83 ± 0.95, 0.76 ± 0.95 METs), and change in peak METs 1 yr after CR (0.98 ± 1.27, 0.75 ± 1.17, 0.36 ± 1.24 METs) were different ( P < .001) among the subgroups. Peak METs at 12 wk and the presence of coexisting conditions were each predictors ( P < .001) of mortality. Improvements in CRF by ≥0.5 METS from baseline to 1-yr follow-up among patients with or without multimorbidity were associated with lower mortality rates.
Increasing CRF by ≥0.5 METs improves survival regardless of multimorbidity status.
本研究的目的是描述多种疾病并存和心肺适能(CRF)对完成心脏康复(CR)患者死亡率的影响。
这项队列研究纳入了1996年1月至2016年3月期间完成12周CR计划的心血管疾病(CVD)病史患者的数据,并随访至2017年3月。患者按是否存在多种疾病并存进行分层,多种疾病并存定义为患有≥2种非传染性疾病(NCDs)。采用Cox回归分析评估多种疾病并存和CRF对完成CR患者死亡率的影响。在基线、CR结束后即刻(12周)完成症状限制性运动试验,其中一个亚组在1年随访时完成另一项试验。根据跑步机速度和坡度确定峰值代谢当量(METs)。
纳入分析的8320例患者(61±10岁,82%为男性)中,5713例(69%)仅诊断为CVD,2232例(27%)患有CVD + 1种NCD,375例(4%)患有CVD +≥2种NCD。各亚组在基线时的峰值METs(7.8±2.0、6.9±2.0、6.1±1.9 METs)、CR结束后即刻峰值METs的变化(0.98±0.98、0.83±0.95、0.76±0.95 METs)以及CR后1年峰值METs的变化(0.98±1.27、0.75±1.17、0.36±1.24 METs)存在差异(P <.001)。12周时的峰值METs和并存疾病的存在均为死亡率的预测因素(P <.001)。无论是否存在多种疾病并存,从基线到1年随访期间CRF提高≥0.5 METS与较低的死亡率相关。
无论多种疾病并存状态如何,将CRF提高≥0.5 METs可改善生存率。